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The present work reports two novel pharmaceutical co-crystals; 2:1 isoniazid-glutaric
acid (INHGA) and 2:1 pyrazinamide-glutaric acid (PGA). Isoniazid and pyrazinamide
are key first-line drugs used for the treatment of tuberculosis. The co-crystals were
produced via solid-state and solvent assisted grinding methods. Thermal characteristics
of the samples were obtained using the differential scanning calorimetry, hot stage
microscopy, and thermogravimetric analyses. The morphology of the powder samples
by scanning electron microscopy, structural analysis by Fourier transform infrared
spectroscopy and powder X-rays diffraction ensured co-crystal formation. Thermal
analyses confirmed the co-crystals with new melting transitions ranging between their
respective starting materials. Unique morphologies of the co-crystal particles were clear
in SEM micrographs. The formation of intermolecular interactions with the co-crystal
former was confirmed by the FT-IR spectral band shifting and was supported by
distinct PXRD patterns of co-crystals thereby authenticating the successful co-crystal
formation. In vitro solubility evaluation of the synthesized co-crystals by HPLC suggested
a remarkable increase in solubility of both INH and PZA in their respective co-crystals.
Keywords: antitubercular, co-crystallization, mechanochemistry, solid-state grinding, liquid-assisted grinding,
characterization, saturation solubility
INTRODUCTION
For centuries, infectious diseases have been the leading cause of death in human existence. Among
known infectious diseases, tuberculosis (TB), an infection caused by Mycobacterium tuberculosis,
and HIV/AIDS caused by the human immunodeficiency virus (HIV) holds the leading rates on
infection (Raviglione and Sulis, 2016) with TB ranked the second killer disease worldwide after
HIV. TB is also known as the oldest infectious disease in history (Pinheiro et al., 2014), yet still
a danger which the battle against is far from over. Compared to the 2012–2013 WHO report,
approximately 8.6 million TB infections were recorded and 1.3 million deaths associated with TB,
10 million new cases, and 1.5 million deaths were reported in 2018. Nonetheless, 58 million lives
have been saved over the period of 10 years (2010–2018) using the current TB treatment strategies
(Baddeley et al., 2013).
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It is estimated that one-fourth of the population worldwide are
infected by latentMycobacterium tuberculosis (Mtb). This serves
as a reservoir for the active and deadly form of the infection,
making it even harder to control the infection. The threat is
further aggravated by the appearance of drug resistance making
treatment very complicated and in some cases resulting in
treatment failure (Somoskovi et al., 2001; Hu et al., 2017; Howard
et al., 2018) and co-infection with HIV/AIDS (Pawlowski et al.,
2012; Mesfin et al., 2014; Bell and Noursadeghi, 2018; Duarte
et al., 2018; Letang et al., 2020).
Despite the advent of drug resistance and several other
drawbacks and inconveniences for patients, the fact remains that
antibiotics have remarkably contributed to the control of TB
and other various infections, saving many lives by reducing the
associated morbidity and mortality rate of bacterial infections
(Aminov, 2010).
As anti-tubercular drugs, isoniazid, chemically known as
isonicotinic acid hydrazide (INH) and pyrazinamide known as
pyrazinecarboxamide (PZA) are two key drugs in the first-line
treatment of TB. Both drugs are used in a single combined
dose concomitant with rifampicin (RIF) and ethambutol (ETB)
or streptomycin. INH and PZA are prodrugs in nature; both
activated after administration, the process triggered by the
bacterial enzymes. The mechanisms of action were thoroughly
explained by Unissa et al. (2016), and INH is the most used drug
in TB treatment. Its potential is well-understood not only by its
activity but also through the meaning of multidrug-resistance
TB (MDR-TB).
However, despite its remarkable activity which seems to
relate to molecular targets of the prokaryotic cells, toxicity and
different side effects (dryness of the mouth, flu-like syndrome,
allergic reactions, peripheral neuritis, mental abnormalities,
methaemoglobinemia, and hepatotoxicity), have been linked to
the use of INH (Sarceviča et al., 2016).
PZA is also a very effective antimycobacterial agent that
offers to the combinations its unique sterilizing activity against
persistent tubercle bacilli during the initial intensive phase of
treatment. The use of PZA is also associated with shortening
the duration of TB treatment, from 9 to 6 months (Somoskovi
et al., 2001; Chiş et al., 2005). PZA shows prodigious but pH-
dependent in-vivo activity. It is effective against M. tuberculosis
only under acidic conditions. However, like many other drugs,
different side effects have been attributed to the prolonged use of
PZA (Schaberg et al., 1996).
Regardless of their substantial contribution, there is evidence
of different strains being resistant to all available antitubercular
drugs as well as different inconveniences (side effects) to patients
caused by the use of high doses required to achieve a better
therapeutic effect. Additionally, while INH and RIF are essential
in the TB treatment regimen, these two drugs present interaction
issues, and the presence of PZA catalyzes their interactions.
Such interactions were also reported during the use of the fixed-
dose combinations containing these three substances with ETB
(Battini et al., 2018). Such interactions may lead to the reduced
activity of the dose, treatment failure, and the appearance of
drug resistance or even advert effects (Scripture and Figg, 2006;
Palleria et al., 2013; Michael et al., 2016).
Due to these setbacks, there is an intense need for new
drugs and novel treatment strategies to improve the treatment
of the infection. The possibility of enhancing the efficacy
of existing drugs is considered a cost-effective approach to
address the mentioned challenges (Aitipamula et al., 2013).
Today, co-crystallization is one of the strategies used to fine-
tune the physicochemical properties of drugs (Patel et al.,
2012; Gadade and Pekamwar, 2016). Co-crystallization uses
principles of crystal engineering to modify the physicochemical
properties of the active pharmaceutical ingredients (APIs) while
maintaining intrinsic drug activity (Duggirala et al., 2016).
Based on this and the fact that a wider range of compounds
readily available to be explored, co-crystallization has become
a preferred approach over salt formation, amorphous forms,
hydrates/solvates and polymorphism.
Pharmaceutical co-crystals which consist of an API and
a pharmaceutically regarded as safe compound bind together
in the crystal lattice (in a very defined stoichiometry),
through intermolecular (non-covalent) interactions among
which hydrogen bonding being the most encountered bonding
type (Sekhon, 2009; Gadade and Pekamwar, 2016; Masodkar
et al., 2018). Different pharmaceutical co-crystals have been
reported. These include that of indomethacin-saccharin (Chun
et al., 2013), pyrazinamide-diflunisal (Évora et al., 2011),
isoniazid-4-aminosalicylic acid co-crystal (Grobelny et al., 2011),
dimethylglyoxime with N-heterocyclic aromatic compounds and
acetamide (Abidi et al., 2017), etc.
Grinding crystalline materials also known as
mechanochemistry has become a method of choice for co-
crystal preparation (Shan and Zaworotko, 2008; Brown, 2012;
Lin, 2016). In this work, mechanochemical reaction as a co-
crystal formation approach, was used to produce two novel
supramolecular co-crystals of the two antitubercular drugs INH
and PZA with glutaric acid (GA). Both drugs have shown the
affinity to form co-crystals with carboxylic acids. Some of the co-
crystals have been reported (Grobelny et al., 2011; Cherukuvada
and Nangia, 2012; Luo and Sun, 2013; Diniz et al., 2018). Two
of the PZA polymorphic co-crystals with dicarboxylic acids
were previously reported and were synthesized via solution
crystallization, and their structures were solved (Aitipamula




All materials used in this project were of analytical grade.
Isoniazid (purity ≥ 99.6%) and pyrazinamide (purity ≥ 98.6%)
and glutaric acid (purity ≥ 99.9%) (structures depicted in
Figure 1). Solvents used were purchased from Sigma-Aldrich
Chemie GmbH (Steinheim, Germany) and were used as received
unless otherwise stated.
Synthesis
Both 2:1 co-crystals INHGA (2:1) and PGA (2:1) were
synthesized using solid-state grinding and solvent-assisted
grinding processes. Initially, the screening for the co-crystal was
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FIGURE 1 | Proposed molecular mechanistic for the formation of (D) INHGA (2:1) and (E) PGA (2:1) co-crystals of (A) isoniazid and (B) pyrazinamide with (C) glutaric
acid as a co-former using solid-state grinding (SSG) and liquid-assisted grinding (LAG).
carried out using solid-state grinding, a method during which the
mixtures INH:GA and PZA:GA in different molar ratios (1:1; 2:1;
1:2) were subjected to milling using a mortar and pestle. Both
co-crystals were reproduced by the milling process assisted by
a few drops of the solvent (ethanol 96%) added to the mixtures
throughout the grinding process. The reproducibility of samples
was ensured by repeating experiments in triplicate.
Physicochemical Characterization
Pure APIs, co-former and the co-crystal samples were
characterized by hot stage microscopy (HSM), differential
scanning calorimetry (DSC), thermogravimetric analysis (TGA),
Fourier transform infrared spectroscopy (FT-IR), scanning
electron microscopy (SEM), and powder X-ray diffraction
(PXRD). All analyses were performed in triplets.
Hot Stage Microscopy (HSM)
Thermo-microscopic analyses were carried out on an optical
microscope Olympus (SZX-ILLB200) equipped with a Linkam
temperature-controlled stage (THMS600/720), connected to a
T95-PE system controller (Linkam Scientific Instruments Ltd.,
Tadworth, Surrey, UK). The hot-stage was calibrated using
USP melting point standards. Images were recorded with an
Olympus UC30 camera attached to the specified microscope
(Olympus Optical, Japan) using Stream Essentials software.
Samples were submerged in silicon oil and subjected to heating
over a temperature range of 30–350◦C at a constant heating rate
of 10◦C/min.
Differential Scanning Calorimetry (DSC)
The DSC measurements were carried out on a DSC 8000 Perkin
Elmer instrument (Waltham, USA), incorporating a cooling
system and a Perkin Elmer nitrogen gas generator. Samples
(2.5–5mg) were crimped in the aluminum pans sealed with
pierced lids. The instrument was calibrated by measuring the
onset temperatures of the melting of indium (m.p. 156.6◦C) and
zinc (m.p. 419.5◦C) while the heat flow was calibrated from the
enthalpy of melting of indium (28.62 J/g). The samples were
heated to 20–30◦C above the melting range of the sample’s
highest melting component, at a heating rate of 10◦C/min. All
analyses were performed under continuous 99.8% dry nitrogen
purging with a flow rate of 20 mL/min.
Thermogravimetry (TGA)
A Perkin-Elmer 4000 PC thermal system (Waltham, USA) was
used. The calibration of the instrument was performed using
three different references; alumel (m.p. = 154.2◦C), Perk alloy
(m.p. = 596◦C) and iron (m.p. = 780◦C) at 1 and 2◦C/min. The
programmed TG technique was carried out over a temperature
range between 30–400◦C at a predetermined heating rate of
10◦C/min. Samples were continuously purged by a stream
of 99.8% dry nitrogen gas (20mL/min) and solvent stoichiometry
of the compounds was determined from the percentagemass loss.
Fourier Transform Infrared Spectrophotometry (FT-IR)
Infra-red spectra of the individual drugs and the co-crystal
samples were obtained using a Perkin-Elmer 100 FTIR
instrument (Waltham, USA) fitted with UATR R© and controlled
with Spectrum software version 6.3.5.0176 for the analysis.
Analyses of powder or crystalline samples were done over the
range of 650–4,000 cm−1 at a 2 cm−1 resolution.
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Scanning Electron Microscopy (SEM)
The morphology of untreated INH, PZA, GA, and co-crystal
samples were conducted using an AURIGA Field Emission
High-Resolution Scanning Electron Microscope (HRSEM), Zeiss
(Germany). Powder samples weremounted onto aluminum stubs
using carbon tape. Accelerating voltage of 5 kV was used for
images and 20 kV for EDS. The lament current was set at 2,359
amps. Carbon tabs were placed on the aluminum stubs to hold
samples. Working distance (WD) for images is displayed on each
image. SmartSEM 90 and AZTEC software were used for imaging
and EDS, respectively.
Powder X-Ray Diffraction (PXRD)
PXRD data were recorded on a D8 Advance powder X-ray
diffractometer (Bruker AXS GmbH, Germany) with CuKα
radiation (Cu-Kα1 = 1.54056 Å). The tube voltage and current
applied were 35 kV and 40mA, respectively. A V20 variable slit
was used. Samples were placed on the sample holder which has
1mm thickness and 1.5 cm in diameter. With a scan rate of 2◦ per
min, sample scan was performed in a continuous scan in locked
coupled mode, within a range of 2θ 5 to 50◦. Origin Pro 8.5. was
used to plot PXRD patterns.
In vitro Solubility Studies
Excess amounts of the individual drugs INH, PZA, and
their respective co-crystals were added to USP aqueous buffer
solutions at pH 1.2 (0.1N hydrochloric acid), 0.2M potassium
phosphate buffer (pH 6.8 and pH 7.4), and deionized water (18.s
M). The mixtures were continuously shaken in an incubator
shaker at 37◦C (± 0.5◦C) and at 100 rpm for 24 h. Samples
were filtered using 0.20µm PVDF syringe filters and analyzed
using an HPLC. INH and PZA in both co-crystal preparations
were quantified using an Agilent HPLC system setting with FXB
Pump (Flexar Binary Pump), an automated injector equipped
with a UV detector (LC 200a Series PDA Detector), and a Flexar
autosampler. Isocratic elution using acetonitrile: water mixed in
30:70 (v/v) solution was applied at a flow rate of 10 mL/min. A
reversed-phase Luna C18 HPLC column 250mm× 4.6mm, 5µm
was used. Injection volume was 10 µL and absorbance of elution
was recorded at 262 and 270 nm following suitable dilutions.
RESULTS AND DISCUSSION
Thermal analysis by DSC confirmed the melting onsets of the
individual drugs INH, PZA, and the co-former GA, respectively
at 172.0, 189.7, and 98.6◦C. The GA DSC curve showed
an additional broad peak at 74.0◦C corresponding to the
polymorphic transition (polymorph-β to α) (Bruni et al., 2013).
The 2:1 co-crystal of isoniazid-glutaric acid (INHGA) exhibited
a single sharp endothermic melt at 106.9◦C (Figure 2). This
melting temperature falls in the range between then INH and GA
melting points.
Themelting onset of the 2:1 pyrazinamide-glutaric acid (PGA)
co-crystal obtained from dry and/or solvent assisted co-grinding,
was found at 102.4◦C. The melting point ranges between melting
temperatures of the PZA and co-former GA. Table 1 summarizes
all the essential thermal properties of the samples.
FIGURE 2 | The DSC curves of pure pentanedioic acid (GA), isoniazid (INH),
pyrazinamide (PZA), and two potential co-crystals INHGA (2:1) and PGA (2:1).
TABLE 1 | Thermal properties for pure INH, PZA, GA, and the two co-crystals
INHGA (2:1) and PGA (2:1) from DSC analyses.
Sample Melting onset temperature (◦C) 1fusH (J/g)
INH 172.0 206.704
INHGA (2:1) 106.9 99.451
GA 98.6 96.711
PGA (2:1) 102.4 99.889
PZA 189.7 227.915
FIGURE 3 | TGA thermograms of (A) PZA, (B) GA, (C) INH, (D) INHGA (2:1)
and (E) PGA (2:1) co-crystal.
These unique melting points were the first indication of
the successful co-crystallization experiments, although further
confirmation by other analytical techniques is warranted since
the change in melting points among multicomponent solid
forms may occur either due to formation of non-covalent
Frontiers in Chemistry | www.frontiersin.org 4 November 2020 | Volume 8 | Article 595908
Ngilirabanga et al. Synthesis of INHGA (2:1) and PGA (2:1) Co-crystals
FIGURE 4 | The FTIR spectra of isoniazid (INH), pentanedioic acid (GA), and INH-GA as a physical mixture and the (2:1) co-crystal.
FIGURE 5 | FTIR spectra of pure pyrazinamide (PZA), PGA (2:1) co-crystal, 2:1 physical mixture, and pure pentanedioic acid (GA).
bonding interaction between API and co-formers, alteration
in packing arrangements (e.g., polymorphic transition, the
formation of eutectic solid mixtures or solid solution).
The fact that a single peak was established during DSC
analysis certainly identifies an interaction between the two
parent compounds.
HSM and TGA experiments were carried out to further
understand the thermal behavior of the co-crystal samples.
The results obtained were subsequently compared to the
DSC data. In both cases, the co-crystals remain stable until
melting temperatures are reached. Results obtained from HSM
(Supplementary Figure 2) and TGA analyses showed no thermal
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TABLE 2 | Summary of the different band shifting in the spectra of the INHGA (2:1) and their functional groups.
Functional groups INH INHGA (2:1) GA Comments
Stretching N–H 3,303 cm−1 3,303 cm−1 – Increased intensity in INHGA (2:1)
Asym C–H 3,107 cm−1 3,101 cm−1 – Shifting of C-H in INHGA (2:1)
Stretching O–H – – 2,954 cm−1 O-H band subsided in the INHGA (2:1)
C–H 3,010 cm−1 – – Disbanded in INHGA (2:1)
O–H – 2,536 cm−1 2,894 cm−1
2,604 cm−1
The band shifted and less intensified
– 1,910 cm−1 A new band in the INHGA (2:1)
Carbonyl C=O 1,663 cm−1 1,704 cm−1 1,683 cm−1 Shifting in INHGA (2:1)
Stretching C=N – 1,633 cm−1 1,632 cm−1 The band is more intensified in INHGA (2:1)
TABLE 3 | Summary of the different band shifting in the spectra of PGA (2:1) and their assignments.
Functional groups PZA PGA (2:1) GA Comments
N–H 3,409 cm−1 3,398 cm−1 Broadening and shift in PGA (2:1)
Sym-N-H 3,288 cm−1 Subsided
Stretching C–H 3,148 cm−1 3,159 cm−1 Bands shifted in PGA (2:1)





Carbonyl C=O 1,704 cm−1 1,694 cm−1 Significant band shifting
Carbonyl C=O 1,662 cm−1 1,686 cm−1 Significant band shifting
changes before melting occurs and correlate with DSC outcomes.
Based on the HSM analysis, GA melted between 98 and 101◦C
range. Co-crystals INHGA (2:1) and PGA (2:1) showed a melt
in the temperature ranges 106–111and 102–108◦C, respectively,
thus matching the DSC results.
TGA thermograms of pure PZA, GA, INH, and both
co-crystals are shown in Figure 3. The TGA thermogram
generated from pure PZA showed a stepwise mass loss with
initial 24.8% loss occurring before and over melting range
(from 150 to 205◦C), suggesting the presence of moisture
in PZA sample. The second mass loss occurred due to the
decomposition of the sample over 205–245◦C temperature range
with 74.1% of mass loss (Figure 3A). GA generated a TGA
thermogram (Figure 3C) showing only a decomposition mass
loss over 150–250◦C.
On the other hand, the TGA thermogram of pure INH
exhibited a stepwise mass loss with decomposition (onset at
229◦C). The first step indicated 81.3% loss of the initial sample
weight followed by 18% loss (Figure 3C).
The mass loss recorded by TGA prior to the melting range
was insignificant (0.0%) for both co-crystals INHGA (2:1), and
PGA (2:1), thus confirming that they are anhydrous and solvent-
free. The TGA curves are further characterized by single steps of
weight loss upon decomposition of the samples which took place
at a high temperature above melting points with a decomposition
and/or evaporation phenomenon at∼180 and 198◦C for INHGA
(2:1), and PGA (2:1), respectively (Figures 3A,B). A total mass
loss of 92.0 and 98.2% was recorded for the respective co-crystals.
Structural studies by FTIR were conducted to confirm the
formation of the co-crystals by monitoring spectral changes of
band positions in the spectra of INHGA (2:1) and PGA (2:1)
co-crystal samples in comparison to pure INH and PZA and co-
former GA. Such changes only occur as a result of intermolecular
interaction between co-formers and confirm if a co-crystal was
formed (Ali et al., 2012; Kumar, 2017). Figures 4, 5 illustrate
IR spectra of INH, PZA, GA, and both INHGA (2:1) and PGA
(2:1) co-crystals.
FTIR spectra of the individual drugs INH, PZA, and GA were
obtained first and were used as references to analyze the co-
crystal spectra. The INH spectrum exhibits two stretching amide
ν(N-H) bands at 3,303 and 3,107 cm−1, stretch ν(C-H) at 3,010
cm−1, while amide stretching carbonyl at 1,663 cm−1 and C=C at
1,633 cm−1 in agreement with the literature (Gunasekaran et al.,
2009; Ravikumar et al., 2013). The FTIR spectrum generated by
GA is mainly characterized by a series of hydroxyl O-H stretching
bands at 2,954, 2,894, and 2,604 cm−1 and the stretching carbonyl
C=O at 1,686 cm−1.
The analysis of the IR spectrum of INHGA (2:1) co-crystal
indicated that the INH carbonyl ν(C=O) stretch band shifted
to 1,656 cm−1 while the GA stretching carbonyl ν(C=O) at
1,686 cm−1 shifted to 1,704 cm−1 due to H-bonding N-H...C=O.
Further, less intensified GA carboxyl ν(O-H) at 2,604 cm−1
significantly shifted to 2,536 cm−1 as a result of H-bonding to
N-H of INH. A new broad absorption peak at 1,910 cm−1 in the
INHGA (2:1) spectrum further indicated the H-bonding effect.
Other shifts identified are illustrated in Table 2.
The FTIR spectra of pure PZA, GA, and PGA (2:1) co-crystal
samples are presented in Figure 5 and Table 3. The significant
differences in the N–H, O-H, and C=O stretching vibrations
confirmed the generation of the indistinguishable co-crystal.
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FIGURE 6 | SEM micrographs of (A) pyrazinamide, (B) isoniazid, (C) PGA (2:1) co-crystal, (D) INHGA (2:1) co-crystal (E) pentanedioic acid, and (F)
isoniazid-pentanedioic acid physical mixture.
The PZA IR spectrum exhibited characteristic bands at
3,410, 3,288, and 3,149 cm−1, respectively, corresponding to
asymmetric and symmetric amides stretching ν(N-H) and
ν(=C-H) stretching. The absorption band at 1,704 cm−1 is
assigned to stretching carbonyl ν(C=O) (Chiş et al., 2005;
Gunasekaran et al., 2009).
Displacement of the PZA asymmetric stretching ν(N-H)
band to 3,398 cm−1 and subsidence of the symmetric ν(N-
H) stretching band in the spectra of PGA (2:1) co-crystal
samples confirmed the contribution of amide N-H in H-
bonding with GA carbonyl. The shifting of both PZA and
GA carbonyl stretching ν(C=O) to 1,699 and 1,662 cm−1
positions in PGA, respectively, further suggested C=O...N-
H bonding. The displacement of GA ν(O-H) stretching
vibration at 2,954/2,604 to 2,931/2,543 cm−1 in the spectrum of
PGA (2:1) co-crystal suggested O-H...N-H H-bonding to PZA
amide ν(N-H).
SEM analysis was carried out to evaluate changes in the
morphology of the co-crystal samples vs. pure untreated
components. SEM micrographs are shown in Figure 6.
INH exhibited dusty irregularly shaped particles with sharp
edges. GA exhibited round shapes and also have smooth surfaces.
The INHGA (2:1) (Figure 6D) co-crystal exhibited a mixture of
fragmented hexagonal and irregularly shaped particles with sharp
surfaces, different from both INH (Figure 6B) and GA, and dusty
aggregates due to the grinding exercise. The physical mixture
sample is composed of the short-range order of particles from
INH and GA (Figure 6F).
The SEM images of untreated PZA, GA, and PGA (2:1) are
presented in Figures 6A,C,E. Pure PZA powder is composed of
large and differently shaped crystals whereas PGA (2:1) powder
from dry grinding is made of small amassed aggregates of round
shapes (see supporting information). Rod-like particles mixed
with round irregularly shaped aggregates with smooth edges were
Frontiers in Chemistry | www.frontiersin.org 7 November 2020 | Volume 8 | Article 595908
Ngilirabanga et al. Synthesis of INHGA (2:1) and PGA (2:1) Co-crystals
observed for the PGA (2:1) co-crystal sample obtained from
solvent assisted grinding.
The co-crystals were further confirmed by PXRD analyses.
In the absence of single X-ray diffraction data for the structure
elucidation, PXRD is a non-destructive tool to confirm the new
phases of the powder samples (Corvis et al., 2010; Padrela et al.,
2012). PXRD authenticated the successful co-crystallization as
previously confirmed by FTIR and other thermal analyses used.
The patterns for the individual drugs and the co-crystal products
are depicted in Figures 7, 8.
Differences in patterns is a clear confirmation of the successful
co-crystal formation. The INH PXRD pattern exhibits peaks
FIGURE 7 | PXRD patterns of pure and calculated isoniazid, pentanedioic
acid, INHGA (2:1) co-crystal, and INH-GA physical mixture.
at 2θ = 11.9, 14.3, 15.6, 16.7, 19.6, 25.3, 26.9, and 27.3◦.
The main diffraction peaks in GA pattern appear at 2θ =
13.8, 19.7, 22.2, and 28.0◦. The INHGA (2:1) PXRD pattern
exhibited new diffraction peaks at 2θ = 18.7, 2, and 27.4◦
(Figure 7), thus confirming the new phase and the successful
co-crystal formation.
The PZA PXRD pattern showed peaks at 2θ = 7.7, 15.5,
17.6, 27.0, and 27.3◦ whereas the pattern generated by co-crystal
sample PGA (2:1) exhibited new peaks at 2θ = 10, 16.5, 20.4,
25.2, and 29.8◦ (Figure 8) and was, therefore, confirmed as a
new phase.
In vitro solubility measurements were obtained using HPLC.
After the necessary dilutions, samples were analyzed using
HPLC at optimum wavelength of 262 and 270 nm detection
for INH and PZA, respectively. The calibration curves for
the two individual drugs INH and PZA were reported with
a regression-squared value of 0.9997 and 0.09999, respectively
(Supplementary Figure 3).
An increase in solubility of 1.7 and 1.3 times, was measured at
acidic pH values 1.2 (0.1N HCl) and 5.8 (PBS) for INHGA (2:1)
co-crystal. At pH 7.4, the solubility increase was less significant
(1.03-times increase) whereas the aqueous solubility of the co-
crystal had slightly decreased. This suggested the influence of pH
on the solubility of the co-crystal and the pure INH.
PGA (2:1) on the other hand, has shown a solubility of 1.5,
1.8, and 1.3-times higher than those recorded for pure PZA,
respectively, in the aqueousmedium, potassium phosphate buffer
at pH 5.8, and 7.4 (Figure 9). Despite an increase in solubility
of PGA (2:1) co-crystal in aqueous solution, the co-crystal
exhibited reduced solubility in acidic medium pH 1,2 (0.1N
HCl), suggesting increased stability of PZA by co-crystallization.
The solubility of the co-crystals may be increased or decreased
FIGURE 8 | PXRD patterns of pure and calculated pyrazinamide, pure and calculated pentanedioic acid, PZA-GA physical mixture and PGA (2:1) co-crystal.
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FIGURE 9 | Histogram comparing the solubility of untreated isoniazid (INH) and pyrazinamide (PZA) to their respective co-crystals INHGA (2:1) and PGA (2:1).
depending on the crystal density and strength of the hydrogen
bond synthons. The higher the crystal packing, the more stable a
co-crystal is and the less soluble it becomes (Rajesh Goud et al.,
2014; Sugandha et al., 2014). Even though no pH-dependence
was observed in pure PZA solubility measurements, its co-
crystal with glutaric acid PGA suggested otherwise. The observed
increase of solubility may further be attributed to reduced
melting points of co-crystals in comparison to the pure APIs.
CONCLUSION
Co-crystals INHGA (2:1) and PGA (2:1) co-crystal were
successfully prepared using co-grinding; a simple, safe, and
cost-effective method. Characterization established different
properties signifying both to be novel co-crystals. Solubility
studies conducted suggested an enhanced solubility of both drugs
as co-crystals, in different pH environments. The co-crystal
formation is known to stabilize unstable drugs (Ranjit and Sarma,
2018), therefore reduced solubility of the co-crystal INHGA (2:1)
in the aqueous medium is plausibly due to an increased stability.
Notably, increased solubility and stability of the co-crystals vs.
individual APIs infer what pharmaceutical formulators desire.
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Sarceviča, I., Kons, A., and Orola, L. (2016). Isoniazid cocrystallisation with
dicarboxylic acids: vapochemical, mechanochemical and thermal methods.
CrystEngComm 18, 1625–1635. doi: 10.1039/C5CE01774B
Schaberg, T., Rebhan, K., and Lode, H. (1996). Risk factors for side-effects of
isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary
tuberculosis. Eur. Respir. J. 9, 2026–2030. doi: 10.1183/09031936.96.09102026
Frontiers in Chemistry | www.frontiersin.org 10 November 2020 | Volume 8 | Article 595908
Ngilirabanga et al. Synthesis of INHGA (2:1) and PGA (2:1) Co-crystals
Scripture, C. D., and Figg, W. D. (2006). Drug interactions in cancer therapy. Nat.
Rev. Cancer 6, 546–558. doi: 10.1038/nrc1887
Sekhon, B. S. (2009). Pharmaceutical co-crystals - a review. Ars Pharmaceut.
50, 99–117. Available online at: http://hdl.handle.net/10481/27459
Shan, N., and Zaworotko, M. J. (2008). The role of cocrystals in pharmaceutical
science. Drug Discov. Today 13, 440–446. doi: 10.1016/j.drudis.2008.03.004
Somoskovi, A., Parsons, L. M., and Salfinger, M. (2001). The molecular basis
of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium
tuberculosis. Respir. Res. 2, 164–168. doi: 10.1186/rr54
Sugandha, K., Kaity, S., Mukherjee, S., Isaac, J., and Ghosh, A. (2014). Solubility
enhancement of ezetimibe by a cocrystal engineering technique. Cryst. Growth
Des. 14, 4475–4486. doi: 10.1021/cg500560w
Unissa, A. N., Subbian, S., Hanna, L. E., and Selvakumar, N. (2016). Overview
on mechanisms of isoniazid action and resistance in Mycobacterium
tuberculosis. Infect. Genet. Evol. 45, 474–492. doi: 10.1016/j.meegid.2016.
09.004
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Ngilirabanga, Aucamp, Pires Rosa and Samsodien. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Chemistry | www.frontiersin.org 11 November 2020 | Volume 8 | Article 595908
